Abstract
Identification of genes and pathways that alter lifespan has allowed for new insights into factors that control the aging process as well as disease. While strong molecular links exist between aging and metabolism, we hypothesize that targeting the mechanisms involved in aging will also give rise to therapeutics that treat other devastating age-related diseases, such as neurodegeneration, cancer, inflammation and cardiovascular disease. Insulin sensitivity, glycemic control and adiposity are not only hallmarks of the major metabolic diseases, type 2 diabetes and obesity, but they also represent significant risk factors for the development of Alzheimers Disease and cognitive impairment. Insulin/IGF-1 signaling is an important pathway regulating aging and disease in a variety of species, including mammals. Here we describe an important role for the gut-derived peptide ghrelin in upstream signaling through the insulin/IGF-1 pathway and exemplify modulation of ghrelin signaling as an approach to mechanistic treatment of multiple age-related diseases by virtue of its ability to regulate key metabolic functions.
Keywords: IGF-1 receptor, Ghrelin, GHSR-1a knockouts, advanced glycation end products, Alzheimer Disease
Current Alzheimer Research
Title: Insulin Resistance, Glycemic Control and Adiposity: Key Determinants of Healthy Lifespan
Volume: 4 Issue: 2
Author(s): Peter S. DiStefano, Rory Curtis and Bradley J. Geddes
Affiliation:
Keywords: IGF-1 receptor, Ghrelin, GHSR-1a knockouts, advanced glycation end products, Alzheimer Disease
Abstract: Identification of genes and pathways that alter lifespan has allowed for new insights into factors that control the aging process as well as disease. While strong molecular links exist between aging and metabolism, we hypothesize that targeting the mechanisms involved in aging will also give rise to therapeutics that treat other devastating age-related diseases, such as neurodegeneration, cancer, inflammation and cardiovascular disease. Insulin sensitivity, glycemic control and adiposity are not only hallmarks of the major metabolic diseases, type 2 diabetes and obesity, but they also represent significant risk factors for the development of Alzheimers Disease and cognitive impairment. Insulin/IGF-1 signaling is an important pathway regulating aging and disease in a variety of species, including mammals. Here we describe an important role for the gut-derived peptide ghrelin in upstream signaling through the insulin/IGF-1 pathway and exemplify modulation of ghrelin signaling as an approach to mechanistic treatment of multiple age-related diseases by virtue of its ability to regulate key metabolic functions.
Export Options
About this article
Cite this article as:
DiStefano S. Peter, Curtis Rory and Geddes J. Bradley, Insulin Resistance, Glycemic Control and Adiposity: Key Determinants of Healthy Lifespan, Current Alzheimer Research 2007; 4 (2) . https://dx.doi.org/10.2174/156720507780362038
DOI https://dx.doi.org/10.2174/156720507780362038 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Therapeutic Targeting of Platelet-Mediated Cellular Interactions in Atherosclerosis and Inflammation
Current Medicinal Chemistry Biocatalysis in the Preparation of the Statin Side Chain
Current Organic Synthesis Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease
Current Neuropharmacology Autonomic Sudomotor Dysfunction in Alzheimers Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Cognitive Consequences of a Sustained Monocyte Type 1 IFN Response in HIV-1 Infection
Current HIV Research Antioxidant SkQ1 Alleviates Signs of Alzheimer’s Disease-like Pathology in Old OXYS Rats by Reversing Mitochondrial Deterioration
Current Alzheimer Research Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis
Current Neuropharmacology Regulation of βAPP and PrPc Cleavage by α-Secretase: Mechanistic and Therapeutic Perspectives
Current Alzheimer Research Editorial [Hot Topic: Drug Targets in Alzheimers Disease (Executive Editors: G. Munch and G. Stuchbury)]
Current Pharmaceutical Design Carbon Monoxide and Iron Modulate Plasmatic Coagulation in Alzheimer’s disease
Current Neurovascular Research Brain Adaptation to Stressful Stimuli: A New Perspective on Potential Therapeutic Approaches Based on BDNF and NMDA Receptors
CNS & Neurological Disorders - Drug Targets Glial Reaction in Parkinsons Diseases: Inflammatory Activation Signaling of Glia as a Potential Therapeutic Target
Current Signal Transduction Therapy Meet the Editorial Board Member
Current Neuropharmacology Memantine: A Therapeutic Approach in Treating Alzheimers and Vascular Dementia
Current Drug Targets - CNS & Neurological Disorders Metals and Parkinson's Disease: Mechanisms and Biochemical Processes
Current Medicinal Chemistry Clinical Applications of MAO-Inhibitors
Current Medicinal Chemistry Hsp20 Protects Neuroblastoma Cells from Ischemia/Reperfusion Injury by Inhibition of Apoptosis via a Mechanism that Involves the Mitochondrial Pathways
Current Neurovascular Research Monitoring Drug Use Among HIV/AIDS Patients in Brazil: Should we Combine Self-Report and Urinalysis?
Current HIV Research RNA G-Quadruplex: The New Potential Targets for Therapy
Current Topics in Medicinal Chemistry Herb-Drug Interactions in Neurological Disorders: A Critical Appraisal
Current Drug Metabolism